GSK gets approvals for ‘bubble boy’ syndrome gene therapy in UK and shingles vaccine in US – Proactive Investors UK
Proactive Investors UK |
GSK gets approvals for 'bubble boy' syndrome gene therapy in UK and shingles vaccine in US
Proactive Investors UK Britain's National Institute for Health and Care Excellence (NICE) said in draft guidance that the Strimvelis gene therapy improves overall survival in patients with adenosine deaminase deficiency, or ADA-SCID, compared with standard stem cell … |
